A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Inclusion Criteria: * This study will enroll pediatric and adult subjects with glaucoma or ocular hypertension receiving treatment with latanoprost in either one or both eyes for at least two weeks. * The pediatric subjects will be grouped by age (0 to \<3 years, 3 to \<12 years, 12 to 18 years). Exclusion Criteria: * Ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the screening visit. * History of ocular trauma or surgery in either eye within 14-days of the screening visit. * Use of continuous wear contact lenses.